Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial

Xun Cao, Hao‐Yang Huang, Chixiong Liang, Zhuochen Lin, Jiayu Zhou, Xi Chen, Yingying Huang, Ze‐Jiang Zhan, Liang‐Ru Ke, Lujun Han, Wei‐Xiong Xia, Lin‐Quan Tang, Shan-Shan Guo, Hu L, Xiang Guo, Xing LvNature Communications 2024 · DOI

TL;DR

This Phase 2 trial investigated the efficacy and safety of combining toripalimab (an anti-PD1 antibody) with capecitabine for patients with residual nasopharyngeal carcinoma (NPC) after definitive treatment. The combination therapy demonstrated promising anti-tumor activity, achieving a high objective response rate and a manageable safety profile, suggesting a potential new treatment avenue for this challenging patient population.

What Problem Does This Paper Address?

Nasopharyngeal carcinoma (NPC) is a cancer with a high incidence in specific geographic regions, and while definitive treatments like chemoradiotherapy are effective, a significant proportion of patients (6.8-13%) are left with residual disease. This residual disease is a strong predictor of poor survival, making its effective management a critical unmet need. Current treatment options for residual NPC, such as re-irradiation or surgery, come with their own set of toxicities and limitations. While immune checkpoint inhibitors (ICIs) like toripalimab have shown success in recurrent or metastatic NPC, their role in treating residual disease after initial therapy had not been systematically evaluated. This paper aims to fill that gap by assessing the efficacy and safety of combining an ICI (toripalimab) with a chemotherapy agent (capecitabine) in this specific patient group.

Methods

This was a single-arm, open-label, Phase 2 clinical trial conducted at Sun Yat-sen University Cancer Centre. The study enrolled 23 patients with histologically or radiologically confirmed residual NPC who were not candidates for re-irradiation or surgery. Patients received six cycles of toripalimab (240 mg intravenously every 3 weeks) in combination with capecitabine (1000 mg/m² orally twice daily for 14 days every 3 weeks). The dosage of capecitabine was modified from standard protocols (1250 mg/m²) to 1000 mg/m² due to concerns about tolerability in the Chinese population, based on previous studies.

The primary endpoint was the objective response rate (ORR) assessed by RECIST (version 1.1) three weeks after completing six cycles of treatment. Secondary endpoints included complete response (CR) rate, disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), safety profile, and treatment compliance. Adverse events were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC-AE) version 5.0.

Datasets

Not discussed in the paper. The study involved patient recruitment and treatment within a clinical trial setting.

Key Insights and Ideas

  • Targeting Residual Disease: The study highlights the potential of combining immune checkpoint blockade with chemotherapy to tackle residual NPC, a challenging clinical scenario with limited treatment options.
  • Synergistic Potential: The rationale for combining toripalimab and capecitabine is rooted in the understanding that chemotherapy can have immunomodulatory effects, potentially enhancing the anti-tumor activity of ICIs.
  • Modified Capecitabine Dosing: The decision to use a modified, lower dose of capecitabine (1000 mg/m²) reflects a pragmatic approach to improve patient tolerability and compliance, particularly in the target population.
  • Manageable Toxicity Profile: Despite the combination therapy, the study reports a manageable safety profile, with no grade 4-5 treatment-related adverse events, suggesting that this regimen can be administered safely.

Key Results

  • High Objective Response Rate: The trial met its primary endpoint, achieving an objective response rate (ORR) of 95.7% (95% CI 78.1-99.9) after six cycles of treatment.
  • Significant Complete Response: A substantial proportion of patients achieved a complete response (CR), with 13 out of 23 patients (56.5%) achieving CR.
  • Disease Control: The disease control rate (DCR) was 100%, indicating that all patients experienced either a response or stable disease.
  • Safety Profile: 91.3% of patients experienced treatment-related adverse events, with the most common being hand-foot syndrome (47.8%). Grade 3 adverse events were observed in 21.7% of patients, with hand-foot syndrome being the most frequent (8.7%). Importantly, no grade 4-5 treatment-related adverse events were recorded.
  • Treatment Compliance: 87% of patients completed the planned six cycles of treatment, demonstrating good compliance.

Limitations and Future Work

The authors acknowledge several limitations:

  • Geographic Specificity: The study was conducted in an endemic region for NPC, and the applicability of these findings to populations outside this region needs to be determined.
  • Prior Fluorouracil Exposure: Previous exposure to fluorouracil in some patients might have influenced the perceived efficacy of capecitabine, although consistent advantages were observed regardless of prior chemotherapy regimens.
  • Plasma EBV DNA Variability: The presence of undetectable plasma Epstein-Barr virus (EBV) DNA in some patients could affect the assessment of residual disease.
  • Adverse Event Attribution: It can be challenging to definitively attribute all adverse events to either toripalimab or capecitabine.
  • Biomarker Analysis: Limited viable tumor cells in biopsies hindered the analysis of predictive genetic biomarkers.

Based on these promising results, the authors suggest that a Phase 3 trial of toripalimab plus capecitabine for residual nasopharyngeal carcinoma is warranted to further validate these findings.

Summary updated

Abstract

Patients with residual nasopharyngeal carcinoma after receiving definitive treatment have poor prognoses. Although immune checkpoint therapies have achieved breakthroughs for treating recurrent and metastatic nasopharyngeal carcinoma, none of these strategies have been assessed for treating residual nasopharyngeal carcinoma. In this single-arm, phase 2 trial, we aimed to evaluate the antitumor efficacy and safety of toripalimab (anti-PD1 antibody) plus capecitabine in patients with residual nasopharyngeal carcinoma after definitive treatment (ChiCTR1900023710). Primary endpoint of this trial was the objective response rate assessed according to RECIST (version 1.1). Secondary endpoints included complete response rate, disease control rate, duration of response, progression-free survival, safety profile, and treatment compliance. Between June 1, 2020, and May 31, 2021, 23 patients were recruited and received six cycles of toripalimab plus capecitabine every 3 weeks. In efficacy analyses, 13 patients (56.5%) had complete response, and 9 patients (39.1%) had partial response, with an objective response rate of 95.7% (95% CI 78.1-99.9). The trial met its prespecified primary endpoint. In safety analyses, 21 of (91.3%) 23 patients had treatment-related adverse events. The most frequently reported adverse event was hand-foot syndrome (11 patients [47.8%]). The most common grade 3 adverse event was hand-foot syndrome (two patients [8.7%]). No grades 4-5 treatment-related adverse events were recorded. This phase 2 trial shows that combining toripalimab with capecitabine has promising antitumour activity and a manageable safety profile for patients with residual nasopharyngeal carcinoma.
BibTeX
@inproceedings{cao2024toripalimab,
  author = {Xun Cao and Hao‐Yang Huang and Chixiong Liang and Zhuochen Lin and Jiayu Zhou and Xi Chen and Yingying Huang and Ze‐Jiang Zhan and Liang‐Ru Ke and Lujun Han and Wei‐Xiong Xia and Lin‐Quan Tang and Shan-Shan Guo and Hu L and Xiang Guo and Xing Lv},
  title = {{Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial}},
  booktitle = {Nature Communications},
  year = {2024},
  doi = {10.1038/s41467-024-45276-1},
}
Figure